OverviewSuggest Edit

Concert Pharmaceuticals is a clinical stage biopharmaceutical company applying its knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. The Company's approach typically starts with approved drugs that may be improved with deuterium substitution. Concert Pharmaceuticals's technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage the known activity of approved drugs to expand into new indications. The Company's deuterated chemical entity platform, or DCE Platform, has broad potential across numerous therapeutic areas.

TypePublic
Founded2006
HQLexington, US
Websiteconcertpharma.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Feb 2019)64
Revenue (FY, 2018)$10.5 M(-92%)
Share Price (Mar 2019)$15.5 (-11%)

Key People/Management at Concert Pharmaceuticals

Roger Tung

Roger Tung

Founder, President, CEO & Board of Directors
Nancy Stuart

Nancy Stuart

COO
Lynette Herscha

Lynette Herscha

General Counsel
James Cassella

James Cassella

Chief Development Officer
Show more

Concert Pharmaceuticals Office Locations

Concert Pharmaceuticals has an office in Lexington
Lexington, US (HQ)
99 Hayden Ave #500
Show all (1)
Report incorrect company information

Concert Pharmaceuticals Financials and Metrics

Concert Pharmaceuticals Revenue

Concert Pharmaceuticals's revenue was reported to be $10.51 m in FY, 2018
USD

Revenue (FY, 2018)

10.5m

Net income (FY, 2018)

(56.0m)

EBIT (FY, 2018)

(55.6m)

Market capitalization (22-Mar-2019)

364.9m

Closing stock price (22-Mar-2019)

15.5

Cash (31-Dec-2018)

17.8m
Concert Pharmaceuticals's current market capitalization is $364.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

66.7m174.0k143.9m10.5m

General and administrative expense

13.1m14.4m21.0m22.9m

R&D expense

28.9m37.0m30.2m43.1m

Operating expense total

41.9m51.3m51.2m66.1m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.6m1.2m4.4m53.4m1.7m56.0k71.0k26.0k20.0k15.0k143.8m11.0k

General and administrative expense

2.5m2.7m3.5m3.3m3.3m3.6m3.8m3.4m5.3m5.7m4.9m5.6m5.5m6.3m

R&D expense

5.6m6.2m8.6m8.4m7.1m10.5m9.8m8.1m8.2m7.3m7.1m8.7m8.9m11.0m

Operating expense total

8.1m9.0m12.0m11.7m10.4m14.0m13.6m11.5m13.5m13.0m12.0m14.3m14.4m17.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

92.5m40.6m27.7m17.8m

Accounts Receivable

70.0k27.0k155.0k15.0k

Current Assets

144.1m97.7m205.7m180.1m

PP&E

2.3m2.2m2.2m8.9m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

24.2m(50.7m)95.6m(56.0m)

Depreciation and Amortization

785.0k893.0k1.0m1.2m

Accounts Payable

(90.0k)44.0k113.0k435.0k

Cash From Operating Activities

23.1m(45.3m)102.9m(48.0m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Concert Pharmaceuticals News and Updates

Report incorrect company information

Concert Pharmaceuticals Blogs

Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019

LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2018 , on Thursday, February 28, 2019 , before the U.S. financial markets open.

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 11, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy

Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

LEXINGTON, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

LEXINGTON, Mass. --(BUSINESS WIRE)--Jan. 22, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.

Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia

LEXINGTON, Mass. --(BUSINESS WIRE)--Dec. 17, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with

Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata

Company On Track to Report Topline Data from the 4 mg and 8 mg Twice-Daily Cohorts in Fourth Quarter of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial
Show more

Concert Pharmaceuticals Frequently Asked Questions

  • When was Concert Pharmaceuticals founded?

    Concert Pharmaceuticals was founded in 2006.

  • Who are Concert Pharmaceuticals key executives?

    Concert Pharmaceuticals's key executives are Roger Tung, Nancy Stuart and Lynette Herscha.

  • How many employees does Concert Pharmaceuticals have?

    Concert Pharmaceuticals has 64 employees.

  • What is Concert Pharmaceuticals revenue?

    Latest Concert Pharmaceuticals annual revenue is $10.5 m.

  • What is Concert Pharmaceuticals revenue per employee?

    Latest Concert Pharmaceuticals revenue per employee is $164.1 k.

  • Who are Concert Pharmaceuticals competitors?

    Competitors of Concert Pharmaceuticals include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Concert Pharmaceuticals headquarters?

    Concert Pharmaceuticals headquarters is located at 99 Hayden Ave #500, Lexington.

  • Where are Concert Pharmaceuticals offices?

    Concert Pharmaceuticals has an office in Lexington.

  • How many offices does Concert Pharmaceuticals have?

    Concert Pharmaceuticals has 1 office.